Physician profile
David L Ogden
NPI 1003887324
$2,073.06
in general payments reported to CMS, 2019-2025
26 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $221 · 2021: $16.28 · 2023: $104 · 2024: $282 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $484.58 | 2024-2025 | |
| Edwards Lifesciences Corporation | $308.30 | 2019-2023 | |
| Boston Scientific Corporation | $171.75 | 2019 | |
| Atricure, INC. | $161.81 | 2025 | Synergy Ablation System |
| Amgen INC. | $137.02 | 2019-2025 | Evenity |
| Lilly USA, LLC | $100.28 | 2019-2025 | Zepbound, Mounjaro |
| Sanofi Pasteur INC. | $93.09 | 2019-2024 | |
| Radius Health, INC. | $72.27 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $63.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $53.18 | 2019-2020 | |
| Astellas Pharma US INC | $50.69 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $49.14 | 2019 | |
| Amarin Pharma, INC. | $24.90 | 2020 | |
| Novo Nordisk INC | $24.60 | 2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.58 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.16 | 2019 | |
| Merck Sharp & Dohme LLC | $19.44 | 2019 | |
| Ironwood Pharmaceuticals, INC | $19.43 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.27 | 2019 | |
| Biodelivery Sciences International, INC. | $16.32 | 2020 | |
| Artivion, INC. | $16.28 | 2021 | |
| Abbott Laboratories | $14.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.